

## Treatment of Plaque-Induced Gingivitis, Chronic Periodontitis, and Other Clinical Conditions\*

This paper has been prepared by the Research, Science and Therapy Committee of the American Academy of Periodontology and is intended for the information of the dental profession. It represents the position of the Academy regarding the current state of knowledge about treatment of plaque-induced gingivitis, chronic periodontitis, and some other clinical conditions. Two other papers entitled *The Pathogenesis of Periodontal Diseases* and *Diagnosis of Periodontal Diseases* also reflect the Academy's position on these subjects. *J Periodontol* 2001;72:1790-1800.

**G**ingivitis and periodontitis are the 2 major forms of inflammatory diseases affecting the periodontium. Their primary etiology is bacterial plaque, which can initiate destruction of the gingival tissues and periodontal attachment apparatus.<sup>1,2</sup> Gingivitis is inflammation of the gingiva that does not result in clinical attachment loss. Periodontitis is inflammation of the gingiva and the adjacent attachment apparatus and is characterized by loss of connective tissue attachment and alveolar bone. Each of these diseases may be subclassified based upon etiology, clinical presentation, or associated complicating factors.<sup>3</sup>

Gingivitis is a reversible disease. Therapy is aimed primarily at reduction of etiologic factors to reduce or eliminate inflammation, thereby allowing gingival tissues to heal. Appropriate supportive periodontal maintenance that includes personal and professional care is important in preventing re-initiation of inflammation.

Therapeutic approaches for periodontitis fall into 2 major categories: 1) anti-infective treatment, which is designed to halt the progression of periodontal attachment loss by removing etiologic factors; and 2) regenerative therapy, which includes anti-infective treatment and is intended to restore structures destroyed by disease. Essential to both treatment approaches is the inclusion of periodontal maintenance procedures.<sup>4</sup>

Inflammation of the periodontium may result from many causes (e.g., bacteria, trauma). However, most forms of gingivitis and periodontitis result from the accumulation of tooth-adherent microorganisms.<sup>5-7</sup> Prominent risk factors for development of chronic periodontitis include the presence of specific subgingival

bacteria,<sup>8-10</sup> tobacco use,<sup>9-13</sup> diabetes,<sup>9,10,14</sup> age,<sup>9,10</sup> and male gender.<sup>9,10</sup> Furthermore, there is evidence that other factors can contribute to periodontal disease pathogenesis: environmental, genetic, and systemic (e.g., diabetes).<sup>14,15</sup>

This paper primarily reviews the treatment of plaque-induced gingivitis and chronic periodontitis, but there might be some situations where the described therapies will not resolve disease or arrest disease progression. Furthermore, the treatments discussed should not be deemed inclusive of all possible therapies, or exclusive of methods of care reasonably directed at obtaining good results. The ultimate decision regarding the appropriateness of any specific procedure must be made by the practitioner in light of the circumstances presented by an individual patient.

### PLAQUE-INDUCED GINGIVITIS

Therapy for individuals with chronic gingivitis is initially directed at reduction of oral bacteria and associated calcified and noncalcified deposits. Patients with chronic gingivitis, but without significant calculus, alterations in gingival morphology, or systemic diseases that affect oral health, may respond to a therapeutic regimen consisting of improved personal plaque control alone.<sup>16</sup> The periodontal literature documents the short- and long-term effects following self-treatment of gingivitis by personal plaque control.<sup>16-20</sup> However, while it may be possible under controlled conditions to remove most plaque with a variety of mechanical oral hygiene aids, many patients lack the motivation or skill to attain and maintain a plaque-free state for significant periods of time.<sup>21-23</sup> Clinical trials also indicate that self-administered plaque control programs alone, without periodic professional reinforcement, are inconsistent in providing long-term inhibition of gingivitis.<sup>19,24,25</sup>

\* This paper was revised under the direction of the Research, Science and Therapy Committee and approved by the Board of Trustees of the American Academy of Periodontology in September 2001.

Many patients with gingivitis have calculus or other associated local factors (e.g., defective dental restorations) that interfere with personal oral hygiene and the ability to remove bacterial plaque. An acceptable therapeutic result for these individuals is usually obtained when personal plaque control measures are performed in conjunction with professional removal of plaque, calculus, and other local contributing factors.<sup>26,27</sup> Removal of dental calculus is accomplished by using hand, sonic, or ultrasonic instruments. The therapeutic objective is to remove plaque and calculus to reduce subgingival bacteria below a threshold level capable of initiating clinical inflammation. The removal of calculus, in gingivitis, usually involves supragingival scaling alone, since the root surfaces are not involved. In cases of gingivitis in a previously treated periodontitis case, there may be some need for root planing. The success of instrumentation is determined by evaluating the periodontal tissues following treatment and during the maintenance phase of therapy.

The use of topical antibacterial agents to help reduce bacterial plaque may be beneficial for the prevention and treatment of gingivitis in some patients.<sup>28-30</sup> A number of these agents in oral rinses and dentifrices have been tested in clinical trials.<sup>28</sup> However, to be accepted by the American Dental Association (ADA) Council on Dental Therapeutics as an effective agent for the treatment of gingivitis, a product must reduce plaque and demonstrate effective reduction of gingival inflammation over a period of at least 6 months. The agent must also be safe and not induce adverse side effects.

Three medicaments have been given the ADA Seal of Acceptance for the control of gingivitis. The active ingredients of one product are thymol, menthol, eucalyptol, and methyl salicylate.<sup>29</sup> Active ingredients in the other two are chlorhexidine digluconate and triclosan.<sup>29</sup> If properly used, the addition of a topical anti-plaque agent to a gingivitis treatment regimen for patients with deficient plaque control will likely result in reduction of gingivitis.<sup>30</sup> However, experimental evidence indicates that penetration of topically applied agents into the gingival crevice is minimal.<sup>31</sup> Therefore, these agents are useful for the control of supragingival, but not subgingival plaque. Among individuals who do not perform excellent oral hygiene, supragingival irrigation with and without medicaments is capable of reducing gingival inflammation beyond that normally achieved by toothbrushing alone. This effect is likely due to the flushing out of subgingival bacteria.<sup>32</sup>

If gingivitis remains following the removal of plaque

and other contributing local factors, thorough evaluation should be undertaken of systemic factors (e.g., diabetes, pregnancy, etc.). If such conditions are present, gingival health may be attained once the systemic problem is resolved and plaque control is maintained.

### **Acute Periodontal Diseases**

Necrotizing ulcerative gingivitis (NUG) is associated with specific bacterial accumulations occurring in individuals with lowered host resistance.<sup>1</sup> NUG usually responds rapidly to the reduction of oral bacteria by a combination of personal plaque control and professional debridement. If lymphadenopathy or fever accompanies oral symptoms, administration of systemic antibiotics may be indicated. The use of chemotherapeutic rinses by the patient may be beneficial during the initial treatment stages. After the acute inflammation of the NUG lesion is resolved, additional intervention may be indicated to prevent disease recurrence or to correct resultant soft tissue deformities.

Necrotizing ulcerative periodontitis (NUP) manifests as rapid necrosis and destruction of the gingiva and periodontal attachment apparatus. It may initiate gingival bleeding and pain, and it usually represents an extension of necrotizing ulcerative gingivitis in individuals with lowered host resistance. NUP has been reported among both HIV-positive and negative individuals, but its true prevalence is unknown.<sup>33-38</sup> Management of NUP involves debridement which may be combined with irrigation with antiseptics (e.g., povidone iodine), antimicrobial mouth rinses (e.g., chlorhexidine), and administration of systemic antibiotics.<sup>39</sup> There is also evidence that HIV-immune deficiency may be associated with severe loss of periodontal attachment that does not necessarily present clinically as an ulcerative lesion.<sup>40</sup> Although not an acute disease, linear gingival erythema (LGE) occurs in some HIV-infected individuals and does not appear to respond to conventional scaling, root planing, and plaque control.<sup>39</sup> Antibiotic therapy should be used in HIV-positive patients with caution due to the possibility of inducing opportunistic infections.<sup>39,40</sup>

The oral manifestations of a primary herpes simplex virus type I infection often include gingivitis. By the time gingivitis is present, patients are usually febrile, in pain, and have lymphadenopathy. Diagnosis is generally made from the clinical appearance of the oral soft tissues. Although not performed routinely, a viral culture may provide definitive identification of the infective agent. In otherwise healthy patients, treatment for herpetic gingivitis consists of

palliative therapy. The infection is self-limiting and usually resolves in 7 to 10 days. Systemic antiviral therapy with acyclovir is appropriate for immunocompromised patients with herpetic gingivitis.<sup>41</sup>

## **Gingival Enlargement**

Chronic gingival inflammation may result in gingival enlargement. This overgrowth of gingiva may be exaggerated in patients with genetic or drug-related systemic factors (e.g., anticonvulsants, cyclosporine and calcium channel blocking drugs).<sup>42-46</sup> Among individuals taking phenytoin, gingival overgrowth may be minimized with appropriate personal oral hygiene and professional maintenance.<sup>47,48</sup> However, root debridement in patients with gingival overgrowth often does not return the periodontium to normal contour. The residual overgrowth may not only complicate the patient's ability to adequately clean the dentition, but it may also present esthetic and functional problems.<sup>49</sup>

For patients with gingival overgrowth, the modification of tissue topography by surgical recontouring may be undertaken to create a maintainable oral environment.<sup>47,50</sup> Postoperative management following tissue resection is important. The benefits of surgical reduction may be lost due to rapid proliferation of the tissues during the post-therapy phase.<sup>51</sup> Recurrence is common in many patients with drug-induced gingival overgrowth.<sup>51</sup> For these patients, consultation with the patient's physician is advisable to determine if it is possible to use an alternative drug therapy that does not induce gingival overgrowth. If not, then repeated surgical and/or non-surgical intervention may be required.

## **CHRONIC PERIODONTITIS**

Appropriate therapy for patients with periodontitis varies considerably with the extent and pattern of attachment loss, local anatomical variations, type of periodontal disease, and therapeutic objectives. Periodontitis destroys the attachment apparatus of teeth resulting in periodontal pocket formation and alteration of normal osseous anatomy. The primary objectives of therapy for patients with chronic periodontitis are to halt disease progression and to resolve inflammation. Therapy at a diseased site is aimed at reducing etiologic factors below the threshold capable of producing breakdown, thereby allowing repair of the affected region. Regeneration of lost periodontal structures can be enhanced by specific procedures. However, many variables responsible for complete

regeneration of the periodontium are unknown and research is ongoing in this area.

## **Scaling and Root Planing**

The beneficial effects of scaling and root planing combined with personal plaque control in the treatment of chronic periodontitis have been validated.<sup>52-65</sup> These include reduction of clinical inflammation, microbial shifts to a less pathogenic subgingival flora, decreased probing depth, gain of clinical attachment, and less disease progression.<sup>52-65</sup>

Scaling and root planing procedures are technically demanding and time-consuming. Studies show that clinical conditions generally improve following root planing; nonetheless, some sites still do not respond to this therapy.<sup>62,63,66,67</sup> The addition of gingival curettage to root planing in the treatment of generalized chronic periodontitis with shallow suprabony pockets does not significantly reduce probing depth or gain clinical attachment beyond that attained by scaling and root planing alone.<sup>68,69</sup> The following factors may limit the success of treatment by root planing: root anatomy (e.g., concavities, furrows etc.), furcations,<sup>66</sup> and deep probing depths.<sup>70-72</sup>

Several weeks following the completion of root planing and efforts to improve personal plaque control, re-evaluation should be conducted to determine the treatment response. Several factors must be considered at sites that continue to exhibit signs of disease. If the patient's daily personal plaque control is not adequate to maintain gingival health, then additional instruction and motivation in personal plaque control and/or the use of topical chemotherapeutics (e.g., mouthrinses, local drug delivery devices) may be indicated. Anatomical factors that can limit the effectiveness of root instrumentation or limit the patient's ability to perform personal plaque control (e.g., deep probing depths, root concavities, furcations) may require additional therapy including surgery. Host response may also have an effect on treatment outcome and patients with systemic conditions (e.g., diabetes, pregnancy, stress, AIDS, immunodeficiencies, and blood dyscrasias) may not respond well to therapy that is directed solely at controlling local factors. In such patients, it is important that attempts be made to control the contributing systemic factors.

## **Pharmacological Therapy**

Pharmacotherapeutics may have an adjunctive role in the management of periodontitis in certain

patients.<sup>73</sup> These adjunctive therapies are categorized by their route of administration to diseased sites: systemic or local drug delivery.

### **Systemic Drug Administration**

Numerous investigations<sup>73</sup> have assessed the use of systemic antibiotics to halt or slow the progression of periodontitis or to improve periodontal status. The adjunctive use of systemically delivered antibiotics may be indicated in the following situations: patients with multiple sites unresponsive to mechanical debridement, acute infections, medically compromised patients, presence of tissue-invasive organisms and ongoing disease progression.<sup>74-77</sup> The administration of antibiotics for the treatment of chronic periodontitis should follow accepted pharmacological principles including, when appropriate, identification of pathogenic organisms and antibiotic sensitivity testing.

Considerable research efforts have focused on systemic application of host modulating agents such as non-steroidal anti-inflammatory drugs (NSAIDs)<sup>78-80</sup> and subantimicrobial dose doxycycline.<sup>81-84</sup> Investigators have reported some benefit when these medications are incorporated into treatment protocols.<sup>78,81-84</sup> Recently [year 2000], the United States Food and Drug Administration (FDA) approved the use of a systemically delivered collagenase inhibitor consisting of a 20-mg capsule of doxycycline hyclate as an adjunct to scaling and root planing for the treatment of periodontitis. Benefits included a statistically significant reduction in probing depths, a gain in clinical attachment levels and a reduction in the incidence of disease progression.<sup>82-84</sup> Overall, the data suggest that use of subantimicrobial dose doxycycline as an adjunct to scaling and root planing provides defined but limited improvement in periodontal status.

It is important to consider the potential benefits and side effects of systemic pharmacological therapy. Benefits may include the ability to treat patients unresponsive to conventional therapy or an individual with multiple sites experiencing recurrent periodontitis. In contrast, potential risks associated with systemically administered antibiotics include development of resistant bacterial strains,<sup>85</sup> emergence of opportunistic infections, and possible allergic sensitization of patients.<sup>73</sup> With regard to the prolonged administration of NSAIDs, harmful effects may include gastrointestinal upset and hemorrhage, renal and hepatic impairment, central nervous system dis-

turbances, inhibition of platelet aggregation, prolonged bleeding time, bone marrow damage, and hypersensitivity reactions.<sup>73</sup> At present, the incidence of negative side effects reported after root planing with or without administration of subantimicrobial dose doxycycline has been similar. In general, since patients with chronic periodontitis respond to conventional therapy, it is unnecessary to routinely administer systemic medications such as antibiotics, NSAIDs, or subantimicrobial dosing with doxycycline.

### **Local Delivery**

Controlled delivery of chemotherapeutic agents within periodontal pockets can alter the pathogenic flora and improve clinical signs of periodontitis.<sup>86-94</sup> Local drug delivery systems provide several benefits; the drug can be delivered to the site of disease activity at a bactericidal concentration and it can facilitate prolonged drug delivery. The FDA has approved the use of an ethylene vinyl acetate fiber that contains tetracycline,<sup>86-91</sup> a gelatin chip that contains chlorhexidine<sup>93</sup> and a minocycline polymer formulation<sup>92</sup> as adjuncts to scaling and root planing. The FDA has also approved doxycycline hyclate in a bioabsorbable polymer gel as a stand-alone therapy for the reduction of probing depths, bleeding upon probing, and gain of clinical attachment.<sup>94</sup>

Local delivery systems have potential limitations and benefits. If used as a monotherapy, problems associated with local delivery can include allergic reaction, possible inability to disrupt biofilms, and failure to remove calculus.<sup>95</sup> The benefits include the ease of application, selectively targeting a limited number of diseased sites that were unresponsive to conventional therapy, and possibly enhanced treatment results at specific locations. Local delivery modalities have shown beneficial clinical improvements with regard to probing depth reduction and gain in clinical attachment.<sup>91-94</sup> Furthermore, there are limited data to suggest that local delivery of antibiotics may also be beneficial in preventing recurrent attachment loss in the absence of maintenance therapy.<sup>90</sup>

Utilization of antibiotics at an individual site will depend on the discretion of the treating therapist after consultation with the patient. The greatest potential of local delivery devices may be to enhance therapy at sites that do not respond to conventional treatment. Ultimately, the results of local drug delivery must be evaluated with regard to the magnitude of

improvement that can be attained relative to disease severity. A more complete review of local drug delivery can be found in the American Academy of Periodontology position paper *The Role of Controlled Drug Delivery for Periodontitis*.<sup>87</sup>

## **Surgical Therapy**

Surgical access to facilitate mechanical instrumentation of the roots has been utilized to treat chronic periodontitis for decades. A surgical approach to the treatment of periodontitis is utilized in an attempt to: 1) provides better access for removal of etiologic factors; 2) reduce deep probing depths; and 3) regenerate or reconstruct lost periodontal tissues.<sup>96-98</sup>

Clinical trials indicate that both surgical and non-surgical approaches can be effective in achieving stability of clinical attachment levels.<sup>60-65,99-103</sup> Flap reflection is capable, however, of increasing the efficacy of root debridement, especially at sites with deep probing depths or furcations.<sup>60-65,70,72,99-104</sup> Nevertheless, complete calculus removal, even with surgical access, may not always be achieved.<sup>70,72,104</sup> The addition of osseous resection during surgical procedures appears to produce greater reduction of probing depth due to gingival recession,<sup>62,64,65</sup> particularly in furcations.<sup>66</sup> Regardless of the type of therapy, furcated teeth are problematic since they are still more likely to lose clinical attachment than nonfurcated teeth.<sup>66,67,105</sup> While these overall findings are helpful, the practitioner should base specific decisions for therapy on findings for each individual patient.

## **Regenerative Surgical Therapy**

The optimal goal of therapy for individuals who have lost a significant amount of periodontal attachment is regeneration of lost tissues. While root debridement in combination with plaque control has demonstrated efficacy in resolving inflammation and arresting periodontitis,<sup>26,27,60-65</sup> healing typically results in the formation of a long junctional epithelium<sup>106-108</sup> with remodeling of the alveolus.<sup>109</sup> Similarly, surgical debridement alone does not induce significant amounts of new connective tissue attachment.<sup>110,111</sup> However, some bone fill may occur in selected sites.<sup>107,112</sup>

Clinical trials suggest that obtaining new periodontal attachment or regenerating lost tissues is enhanced by the use of adjunctive surgical technique devices and materials. Chemical agents that modify the root surface, while promoting new attach-

ment, have shown variable results when used in humans.<sup>113-118</sup> Bone grafting<sup>119-125</sup> and guided tissue regeneration (GTR) techniques, with or without bone replacement grafts,<sup>126-133</sup> may be successful when used at selected sites with advanced attachment loss. The use of biologically engineered tissue inductive proteins (e.g., growth factors, extracellular matrix proteins, and bone morphogenic proteins) to stimulate periodontal or osseous regeneration has also shown promise.<sup>134-142</sup> Literature reviews on periodontal regeneration<sup>143,144</sup> and mucogingival therapy<sup>145</sup> provide additional information regarding these therapies.

Regenerative therapy and other treatment modalities can be affected by several risk factors (e.g., diabetes and tobacco use) which can diminish periodontal treatment outcomes.<sup>146</sup> In this regard, cigarette smoking is associated with a high risk for progressive periodontitis.<sup>9-13,147</sup> and treatment for periodontitis may be less effective in smokers than non-smokers.<sup>148-150</sup> These factors are reviewed in more depth in the Academy's position paper *Tobacco Use and the Periodontal Patient*.<sup>151</sup> To maximize effective prevention and treatment of periodontitis, patients should be encouraged to stop smoking and to stop using smokeless tobacco.

## **OCCLUSAL MANAGEMENT**

Several studies indicated that excessive occlusal forces do not initiate plaque-induced periodontal disease or connective tissue attachment loss (periodontitis).<sup>152-155</sup> However, other investigations suggest that tooth mobility may be associated with adverse effects on the periodontium and affect the response to therapy with respect to gaining clinical attachment.<sup>156,157</sup> With regards to treatment, occlusal therapy may aid in reducing tooth mobility and gaining some bone lost due to traumatic occlusal forces.<sup>158</sup> Occlusal equilibration also may be used to ameliorate a variety of clinical problems related to occlusal instability and restorative needs.<sup>159</sup> Clinician's should use their judgment as to whether or not to perform an occlusal adjustment as a component of periodontal therapy based upon an evaluation of clinical factors related to patient comfort, health and function.<sup>160</sup>

## **PERIODONTAL MAINTENANCE PROCEDURES**

Periodic monitoring of periodontal status and appropriate maintenance procedures should be part of the long-term treatment plan for managing chronic peri-

odontitis.<sup>28</sup> Although experimental studies have demonstrated very successful treatment outcomes when patients are professionally maintained at 2-week intervals,<sup>161</sup> such a program is impractical for most chronic periodontitis patients. Therefore, to maximize successful therapeutic outcomes, patients must maintain effective daily plaque control. It also appears that in-office periodontal maintenance at 3 to 4 month intervals can be effective in maintaining most patients.<sup>4</sup> A more comprehensive review on this subject can be found in the American Academy of Periodontology's position paper entitled *Supportive Periodontal Therapy (SPT)*.<sup>162</sup>

### SUMMARY

The inflammatory components of plaque induced gingivitis and chronic periodontitis can be managed effectively for the majority of patients with a plaque control program and non-surgical and/or surgical root debridement coupled with continued periodontal maintenance procedures. Some patients may need additional therapeutic procedures. All of the therapeutic modalities reviewed in this position paper may be utilized by the clinician at various times over the long-term management of the patient's periodontal condition.

### ACKNOWLEDGMENTS

This paper was revised by Dr. Paul S. Rosen. It replaces the paper entitled *Treatment of Gingivitis and Periodontitis* which was authored by Drs. William F. Ammons, Kenneth L. Kalkwarf, and Stephen T. Sonis in May 1993 and revised by Dr. Bruce L. Pihlstrom and William F. Ammons in September 1997. Members of the 2000-2001 Research, Science and Therapy Committee include: Drs. David Cochran, Chair; Timothy Blieden; Otis J. Bouwsma; Robert E. Cohen; Petros Damoulis; Connie H. Drisko; Joseph P. Fiorellini; Gary Greenstein; Vincent J. Iacono; Martha J. Somerman; Terry D. Rees; Angelo Mariotti, Consultant; Robert J. Genco, Consultant; and Brian L. Mealey, Board Liaison.

### REFERENCES

1. The American Academy of Periodontology. The pathogenesis of periodontal diseases (position paper). *J Periodontol* 1999;70:457-470.
2. The American Academy of Periodontology. *Diagnosis of Periodontal Diseases* (position paper). Chicago: The American Academy of Periodontology; April 1995.
3. Armitage GC. Development of a classification system

- for periodontal diseases and conditions. *Ann Periodontol* 1999;4:1-6.
4. Ramfjord SP. Maintenance care and supportive periodontal therapy. *Quintessence Int* 1993;24:465-471.
5. Page RC. Gingivitis. *J Clin Periodontol* 1986;13:345-359.
6. Ranney RR, Debski BF, Tew JG. Pathogenesis of gingivitis and periodontal disease in children and young adults. *Pediatr Dent* 1981;3:89-100.
7. Socransky SS, Haffajee AD. Microbial mechanisms in the pathogenesis of destructive periodontal diseases: A critical assessment. *J Periodont Res* 1991;26:195-212.
8. Wolff L, Dahlen G, Aeppli D. Bacteria as risk markers for periodontitis. *J Periodontol* 1994;65:498-510.
9. Grossi SG, Zambon JJ, Ho AW, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. *J Periodontol* 1994;65:260-267.
10. Grossi SG, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. *J Periodontol* 1995;66:23-29.
11. Ismail A, Morrison E, Burt B, Caffesse R, Kavanaugh M. Natural history of periodontal disease in adults: Findings from the Tecumseh Periodontal Disease Study, 1959-1987. *J Dent Res* 1990;69:430-435.
12. Haber J, Wattles J, Crowley M, Mandell R, Joshipurak K, Kent RL. Evidence for cigarette smoking as a major risk factor for periodontitis. *J Periodontol* 1993;64:16-23.
13. Bergstrom J, Preber H. Tobacco use as a risk factor. *J Periodontol* 1994;65:545-550.
14. Oliver RC, Tervonen T. Diabetes - a risk factor for periodontitis in adults? *J Periodontol* 1994;65:530-538.
15. Michalowicz BS. Genetic and heritable risk factors in periodontal disease. *J Periodontol* 1994;65:479-488.
16. Loe H, Theilade E, Jensen SB. Experimental gingivitis in man. *J Periodontol* 1965;36:177-187.
17. Theilade E, Wright WH, Jensen SB, Loe H. Experimental gingivitis in man. II. A longitudinal clinical and bacteriological investigation. *J Periodont Res* 1966;1:1-13.
18. Lindhe J, Axelsson P. The effect of a preventive programme on dental plaque, gingivitis, and caries in school children. Results after one and two years. *J Clin Periodontol* 1974;1:126-138.
19. Suomi JD, Greene JC, Vermillion JR, Doyle J, Chang JJ, Leatherwood EC. The effect of controlled oral hygiene procedures on the progression of periodontal disease in adults: Results after third and final year. *J Periodontol* 1971;42:152-160.
20. Axelsson P, Lindhe J. Effect of controlled oral hygiene procedures on caries and periodontal disease in adults. Results after 6 years. *J Clin Periodontol* 1981;8:239-248.
21. De la Rosa M, Guerra JZ, Johnston DA, Radike AW. Plaque growth and removal with daily toothbrushing. *J Periodontol* 1979;50:661-664.
22. MacGregor IDM, Rugg-Gunn AJ, Gordon PH. Plaque levels in relation to the number of toothbrushing strokes in un instructed English schoolchildren. *J Peri-*

- odont Res* 1986;21:577-582.
23. Lang NP, Cumming BR, Løe H. Toothbrushing frequency as it relates to plaque development and gingival health. *J Periodontol* 1973;44:396-405.
  24. Listgarten MA, Schifter CC, Laster L. 3-year longitudinal study of the periodontal status of an adult population with gingivitis. *J Clin Periodontol* 1985;12:225-238.
  25. Agerbaek N, Melsen B, Lind OP, Glavind L, Kristiansen B. Effect of regular small group instruction per se on oral health status of Danish schoolchildren. *Community Dent Oral Epidemiol* 1979;7:17-20.
  26. Tagge DL, O'Leary TJ, El-Kafrawy AH. The clinical and histological response of periodontal pockets to root planing and oral hygiene. *J Periodontol* 1975;46:527-533.
  27. Lövdal A, Arno A, Schei O, Waerhaug J. Combined effect of subgingival scaling and controlled oral hygiene on the incidence of gingivitis. *Acta Odontol Scand* 1961;19:537-555.
  28. Hancock EB. Prevention. *Ann Periodontol* 1996;1:223-249.
  29. Mandel ID. Antimicrobial mouthrinses: overview and update. *J Am Dent Assoc* 1994;125(Suppl. 2):2S-10S.
  30. Brex M, Brownstone E, MacDonald L, Gelskey S, Cheang M. Efficacy of Listerine, Meridol, and chlorhexidine as supplements to regular tooth-cleaning measures. *J Clin Periodontol* 1992;19:202-207.
  31. Pitcher GR, Newman HN, Strahan JD. Access to subgingival plaque by disclosing agents using mouthrinsing and direct irrigation. *J Clin Periodontol* 1980;7:300-308.
  32. The American Academy of Periodontology. *The Role of Supra- and Subgingival Irrigation in the Treatment of Periodontal Diseases* (position paper). Chicago: The American Academy of Periodontology; April 1995.
  33. Mealey BL. Periodontal implications: Medically compromised patients. *Ann Periodontol* 1996;1:293-303.
  34. Drinkard CR, Decher L, Little JW, et al. Periodontal status of individuals in early stages of human immunodeficiency virus infection. *Community Dent Oral Epidemiol* 1991;19:281-285.
  35. Friedman RB, Gunsolley J, Gentry A, Dinius A, Kaplowitz L, Settle J. Periodontal status of HIV-seropositive and AIDS patients. *J Periodontol* 1991;62:623-627.
  36. Riley C, London JP, Burmeister JA. Periodontal health in 200 HIV-positive patients. *J Oral Pathol Med* 1992;21:124-127.
  37. Masouedis CM, Katz MH, Greenspan D, et al. Prevalence of HIV-associated periodontitis and gingivitis in HIV-infected patients attending an AIDS clinic. *J Acquir Immune Defic Syndr* 1992;5:479-83.
  38. Glick M, Muzyka BC, Salkin LM, Lurie D. Necrotizing ulcerative periodontitis: A marker for immune deterioration and a predictor for the diagnosis of AIDS. *J Periodontol* 1994;65:393-397.
  39. The American Academy of Periodontology. *Periodontal Considerations in the HIV-Positive Patient* (position paper). Chicago: The American Academy of Periodontology; April 1994.
  40. Tomar SL, Swango PA, Kleinman DV, Burt BA. Loss of periodontal attachment in HIV-seropositive military personnel. *J Periodontol* 1995;66:421-428.
  41. Redding SW, Montgomery MT. Acyclovir prophylaxis for oral herpes simplex infection in patients with bone marrow transplants. *Oral Surg Oral Med Oral Pathol* 1989;67:680-683.
  42. Hassell TM, Hefti AF. Drug induced gingival overgrowth: Old problem, new problem. *Crit Rev Oral Biol Med* 1991;2:103-137.
  43. Butler RT, Kalkwarf KL, Kaldahl WB. Drug-induced gingival hyperplasia: phenytoin, cyclosporine and nifedipine. *J Am Dent Assoc* 1987;114:56-60.
  44. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. *J Periodontol* 1992;63:453-456.
  45. Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. *J Periodontol* 1995;66:572-578.
  46. Mealey BL. Periodontal implications: Medically compromised patients. *Ann Periodontol* 1996;1:303-308.
  47. Pihlstrom B. Prevention and treatment of dilantin-associated gingival enlargement. *Compendium Continuing Educ Dent* 1990;11(Suppl.14):S506-S510.
  48. Hall WB. Dilantin hyperplasia: a preventable lesion? *Compendium Continuing Educ Dent* 1990;11(Suppl. 14):S502-505.
  49. Jones JE, Weddell JA, McKown CG. Incidence and indications for surgical management of phenytoin-induced gingival overgrowth in a cerebral palsy population. *J Oral Maxillofac Surg* 1998;46:385-390.
  50. Hall EE. Prevention and treatment considerations in patients with drug-induced gingival enlargement. *Curr Opin Periodontol* 1997;4:59-63.
  51. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. *J Periodontol* 1999;70:967-972.
  52. Morrison EC, Ramfjord SP, Hill RW. Short-term effects of initial, nonsurgical periodontal treatment (hygienic phase). *J Clin Periodontol* 1980;7:199-211.
  53. Garrett JS. Effects of nonsurgical periodontal therapy on periodontitis in humans. A review. *J Clin Periodontol* 1983;10:515-523.
  54. Badersten A, Nilveus R, Egelberg J. Effect of non-surgical periodontal therapy. I. Moderately advanced periodontitis. *J Clin Periodontol* 1981;8:57-72.
  55. Badersten A, Nilveus R, Egelberg J. Effect of non-surgical periodontal therapy. II. Severely advanced periodontitis. *J Clin Periodontol* 1984;11:63-76.
  56. Badersten A, Nilveus R, Egelberg J. Effect of non-surgical periodontal therapy. III. Single versus repeated instrumentation. *J Clin Periodontol* 1984;11:114-124.
  57. Hughes TP, Caffesse RG. Gingival changes following scaling, root planing and oral hygiene - a biometric evaluation. *J Periodontol* 1978;49:245-252.
  58. Magnusson I, Lindhe J, Yoneyama T, Liljenberg B. Recolonization of subgingival microbiota following scaling in deep pockets. *J Clin Periodontol* 1984;11:193-207.
  59. Mosques T, Listgarten MA, Phillips RW. Effect of scaling and root planing on the composition of the human subgingival microbial flora. *J Periodont Res* 1980;15:

- 144-151.
60. Pihlstrom BL, McHugh RB, Oliphant TH, Ortiz-Campos C. Comparison of surgical and nonsurgical treatment of periodontal disease. A review of current studies and additional results after 6-1/2 years. *J Clin Periodontol* 1983;10:524-544.
  61. Hill RW, Ramfjord SP, Morrison EC, et al. Four types of periodontal treatment compared over two years. *J Periodontol* 1981;52:655-662.
  62. Kaldahl WB, Kalkwarf KL, Patil KD, Dyer JK, Bates RE Jr. Evaluation of four modalities of periodontal therapy. Mean probing depth, probing attachment level and recession changes. *J Periodontol* 1988;59:783-793.
  63. Becker W, Becker BE, Ochsenein C, et al. A longitudinal study comparing scaling, osseous surgery and modified Widman procedures. Results after one year. *J Periodontol* 1988;59:351-365.
  64. Ramfjord SP, Caffesse RG, Morrison EC, et al. 4 modalities of periodontal treatment compared over 5 years. *J Clin Periodontol* 1987;14:445-452.
  65. Kaldahl WB, Kalkwarf KL, Kashinath D, Patil D, Molvar MP, Dyer JK. Long-term evaluation of periodontal therapy: I. Response to 4 therapeutic modalities. *J Periodontol* 1996;67:93-102.
  66. Kalkwarf KL, Kaldahl WB, Patil KD. Evaluation of furcation region response to periodontal therapy. *J Periodontol* 1988;59:794-804.
  67. Kaldahl WB, Kalkwarf KL, Kashinath D, Patil D, Molvar MP, Dyer JK. Long-term evaluation of periodontal therapy: II. Incidence of sites breaking down. *J Periodontol* 1996;67:103-108.
  68. Ainslie P, Caffesse R. A biometric evaluation of gingival curettage (II). *Quintessence Int* 1981;6:609-614.
  69. Echeverra JJ, Caffesse RG. Effects of gingival curettage when performed 1 month after root instrumentation. A biometric evaluation. *J Clin Periodontol* 1983;10:277-286.
  70. Caffesse RG, Sweeney PL, Smith BA. Scaling and root planing with and without periodontal flap surgery. *J Clin Periodontol* 1986;13:205-210.
  71. Rabbani GM, Ash MM, Caffesse RG. The effectiveness of subgingival scaling and root planing in calculus removal. *J Periodontol* 1981;52:119-123.
  72. Fleischer HC, Mellonig JT, Brayer WK, Gray JL, Barnett JD. Scaling and root planing efficacy in multi-rooted teeth. *J Periodontol* 1989;60:402-409.
  73. Drisko CH. Non-surgical pocket therapy: Pharmacotherapeutics. *Ann Periodontol* 1996;1:491-566.
  74. Magnusson I, Low SB, McArthur WP, et al. Treatment of subjects with refractory periodontal disease. *J Clin Periodontol* 1994;21:628-637.
  75. van Winkelhoff AJ, Tjihof CJ, de Graaff J. Microbiological and clinical results of metronidazole plus amoxicillin therapy in *Actinobacillus actinomycetemcomitans*-associated periodontitis. *J Periodontol* 1992;63:52-57.
  76. Magnusson I, Clark WB, Low SB, Maruniak J, Marks RG, Walker CB. Effect of non-surgical periodontal therapy combined with adjunctive antibiotics in subjects with "refractory" periodontal disease. I. Clinical results. *J Clin Periodontol* 1989;16:647-653.
  77. Kornman KS, Robertson PB. Clinical and microbiological evaluation of therapy for juvenile periodontitis. *J Periodontol* 1985;56:443-446.
  78. Williams R, Jeffcoat M, Howell T, et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. *J Periodontol* 1989;60:485-490.
  79. Williams RC, Jeffcoat MK, Howell TH, et al. Ibuprofen: An inhibitor of alveolar bone resorption in beagles. *J Periodont Res* 1988;23:225-229.
  80. Howell TH, Jeffcoat MK, Goldhaber P, et al. Inhibition of alveolar bone loss in beagles with the NSAID naproxen. *J Periodont Res* 1991;26:498-501.
  81. Crouth RJ, Lee HM, Schroeder H, et al. The "cyclic" regimen of low-dose doxycycline for adult periodontitis: A preliminary study. *J Periodontol* 1996;67:506-514.
  82. Golub LM, McNamara TF, Ryan ME, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. *J Clin Periodontol* 2001;28:146-156.
  83. Caton J. Evaluation of Periostat for patient management. *Compend Continuing Educ Dent* 1999;20:451-462.
  84. Caton J, Ciancio SG, Bleiden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. *J Periodontol* 2000;71:521-532.
  85. Walker CB. The acquisition of antibiotic resistance in the periodontal microflora. *Periodontol* 2000 1996;10:79-88.
  86. Goodson JM, Cugini MA, Kent RL, et al. Multicenter evaluation of tetracycline fiber therapy: II. Clinical response. *J Periodont Res* 1991;26:371-379.
  87. The American Academy of Periodontology. The role of controlled drug delivery for periodontitis (position paper). *J Periodontol* 2000;71:125-140.
  88. Goodson JM, Tanner A, McArdle S, Dix K, Watanabe SM. Multicenter evaluation of tetracycline fiber therapy: III. Microbiological response. *J Periodont Res* 1991;26:440-451.
  89. Drisko CH, Cobb CM, Killoy WJ, et al. Evaluation of periodontal treatments using controlled release tetracycline fibers: Clinical response. *J Periodontol* 1995;66:692-699.
  90. Michalowicz BS, Pihlstrom BL, Drisko CH, et al. Evaluation of periodontal treatments using controlled-release tetracycline fibers: Maintenance response. *J Periodontol* 1995;66:708-715.
  91. Newman MG, Kornman KS, Doherty FM. A 6-month multi-center evaluation of adjunctive tetracycline fiber therapy used in conjunction with scaling and root planing in maintenance patients: clinical results. *J Periodontol* 1994;65:685-691.
  92. Williams RC, Paquette DW, Offenbacher S, Adams DF, Armitage GC, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled clinical trial. *J Periodontol* 2001; in Press.
  93. Jeffcoat MK, Bray KS, Ciancio SG, et al. Adjunctive

- use of a subgingival controlled-release chlorhexidine chip reduces probing depth and improves attachment level compared with scaling and root planing alone. *J Periodontol* 1998;69:989-997.
94. Garrett S, Johnson L, Drisko CH, et al. Two multi-center studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. *J Periodontol* 1999;70:490-503.
  95. Darveau PR, Tanner A, Page RC. The microbial challenge in periodontics. *Periodontol 2000* 1997;14:12-32.
  96. Consensus Report: Surgical pocket therapy. *Ann Periodontol* 1996;1:618-620.
  97. Consensus Report: Periodontal regeneration around natural teeth. *Ann Periodontol* 1996;1:667-670.
  98. Consensus Report: Mucogingival therapy. *Ann Periodontol* 1996;1:702-706.
  99. Antczak-Bouckoms A, Joshipura K, Burdick E, Tolloch JFC. Meta-analysis of surgical versus non-surgical methods of treatment for periodontal disease. *J Clin Periodontol* 1993;20:259-268.
  100. Ramfjord SP, Knowles JW, Nissle RR, Schick RA, Burgett FG. Longitudinal study of periodontal therapy. *J Periodontol* 1973;44:66-77.
  101. Pihlstrom BL, Oliphant TH, McHugh RB. Molar and nonmolar teeth compared over 6 1/2 years following two methods of periodontal therapy. *J Periodontol* 1984;55:499-504.
  102. Lindhe J, Westfelt E, Nyman S, Socransky S, Heijl L, Bratthall G. Healing following surgical/nonsurgical treatment of periodontal disease. A clinical study. *J Clin Periodontol* 1982;9:115-128.
  103. Berkey CS, Antczak-Bouckoms A, Hoaglin DC, Mosteller F, Pihlstrom BL. Multiple-outcomes meta-analysis of treatments for periodontal disease. *J Dent Res* 1995;74:1030-1039.
  104. Buchanan SA, Robertson PB. Calculus removal by scaling/root planing with and without surgical access. *J Periodontol* 1987;58:159-163.
  105. Wang HL, Burgett FG, Shyr Y, Ramfjord S. The influence of molar furcation involvement and mobility on future clinical periodontal attachment loss. *J Periodontol* 1994;65:25-29.
  106. Caton JG, Zander HA. The attachment between tooth and gingival tissues after periodic root planing and soft tissue curettage. *J Periodontol* 1979;50:462-466.
  107. Caton J, Nyman S. Histometric evaluation of periodontal surgery. I. The modified Widman flap procedure. *J Clin Periodontol* 1980;7:212-223.
  108. Caton J, Nyman S, Zander H. Histometric evaluation of periodontal surgery. II. Connective tissue attachment levels after four regenerative procedures. *J Clin Periodontol* 1980;7:224-231.
  109. Isidor F, Attström R, Karring T. Regeneration of alveolar bone following surgical and non-surgical periodontal treatment. *J Clin Periodontol* 1985;12:687-696.
  110. Listgarten MA, Rosenberg MM. Histological study of repair following new attachment procedures in human periodontal lesions. *J Periodontol* 1979;50:333-344.
  111. Stahl SS, Froum SJ, Kushner L. Periodontal healing following open flap debridement procedures. II. Histologic observations. *J Periodontol* 1982;53:15-21.
  112. Froum SJ, Coran M, Thaller B, Kushner L, Scopp IW, Stahl SS. Periodontal healing following open debridement procedures. I. Clinical assessment of soft tissue and osseous repair. *J Periodontol* 1982;53:8-14.
  113. Cole RT, Crigger M, Bogle G, Egelberg J, Selvig KA. Connective tissue regeneration to periodontally diseased teeth. A histological study. *J Periodont Res* 1980;15:1-9.
  114. Albair WB, Cobb CM, Killoy WJ. Connective tissue attachment to periodontally diseased roots after citric acid demineralization. *J Periodontol* 1982;53:515-526.
  115. Froum SJ, Kushner L, Stahl SS. Healing responses of human intraosseous lesions following the use of debridement, grafting and citric acid root treatment. I. Clinical and histologic observations six months post-surgery. *J Periodontol* 1983;54:67-76.
  116. Stahl SS, Froum SJ, Kushner L. Healing responses of human intraosseous lesions following the use of debridement, grafting and citric acid root treatment. II. Clinical and histologic observations: One year post-surgery. *J Periodontol* 1983;54:325-338.
  117. Peltzman B, Bowers GM, Reddi AH, Bergquist JJ. Treatment of furcations involvements with Fibronectin and intraoral autogenous bone grafts: Preliminary observations. *Int J Periodontics Restorative Dent* 1988;8(5):51-63.
  118. Wikesjö UME, Baker PJ, Christersson LA, et al. A biochemical approach to periodontal regeneration: Tetracycline treatment conditions dentin surfaces. *J Periodont Res* 1986;21:322-329.
  119. Dragoo MR, Sullivan HC. A clinical and histologic evaluation of autogenous iliac bone grafts in humans: Part I. Wound healing 2 to 8 months. *J Periodontol* 1973;44:599-613.
  120. Dragoo MR, Sullivan HC. A clinical and histologic evaluation of autogenous iliac bone grafts in humans: Part II. External root resorption. *J Periodontol* 1973;44:614-625.
  121. Mellonig JT. Decalcified freeze-dried bone allograft as an implant material in human periodontal defects. *Int J Periodontics Restorative Dent* 1984;4(6):40-55.
  122. Bowers GM, Chadroff B, Carnevale R, et al. Histologic evaluation of new human attachment apparatus formation in humans, Part I. *J Periodontol* 1989;60:664-674.
  123. Bowers GM, Chadroff B, Carnevale R, et al. Histologic evaluation of new human attachment apparatus formation in humans, Part II. *J Periodontol* 1989;60:675-682.
  124. Bowers GM, Chadroff B, Carnevale R, et al. Histologic evaluation of new human attachment apparatus formation in humans, Part III. *J Periodontol* 1989;60:683-693.
  125. Rummelhart JM, Mellonig JT, Gray JL, Towle HJ. A comparison of freeze-dried bone allograft and demineralized freeze-dried bone allograft in human periodontal osseous defects. *J Periodontol* 1989;60:655-663.
  126. Gottlow J, Nyman S, Karring T, Lindhe J. New attachment formation as the result of controlled tis-

- sue regeneration. *J Clin Periodontol* 1984;11:494-503.
127. Magnusson I, Nyman S, Karring T, Egelberg J. Connective tissue attachment formation following exclusion of gingival connective tissue and epithelium during healing. *J Periodontol Res* 1985;20:201-208.
  128. Becker W, Becker BE, Berg L, Prichard J, Caffesse R, Rosenberg E. New attachment after treatment with root isolation procedures: Report for treated class III and class II furcations and vertical osseous defects. *Int J Periodontics Restorative Dent* 1988;8(3):9-23.
  129. McClain PH, Schallhorn RG. Long-term assessment of combined osseous composite grafting, root conditioning, and guided tissue regeneration. *Int J Periodontics Restorative Dent* 1993;13:9-27.
  130. Machtei EE, Grossi SG, Dunford R, Zambon JJ, Genco RJ. Long-term stability of Class II furcation defects treated with barrier membranes. *J Periodontol* 1996;67:523-527.
  131. Garrett S, Polson AM, Stoller NH, et al. Comparison of a bioresorbable GTR barrier to a non-absorbable barrier in treating human class II furcation defects. A multi-center parallel design randomized single-blind trial. *J Periodontol* 1997;68:667-675.
  132. Rosen PS, Reynolds MA. Polymer-assisted regenerative therapy: case reports of 22 consecutively treated periodontal defects with a novel combined surgical approach. *J Periodontol* 1999;70:554-561
  133. Cortellini P, Pini Prato G, Tonetti MS. Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trial. *J Periodontol* 1996;67:217-223.
  134. Bowers G, Felton F, Middleton C, et al. Histologic comparison of regeneration in human intrabony defects when osteogenin is combined with demineralized freeze-dried bone allograft and with purified bovine collagen. *J Periodontol* 1991;62:690-702.
  135. Caffesse RG, Quinones CR. Polypeptide growth factors and attachment proteins in periodontal wound healing and regeneration. *Periodontol 2000* 1993;1:69-79.
  136. Seyedin SM. Osteoinduction: A report on the discovery and research of unique protein growth factors mediating bone development. *Oral Surg Oral Med Oral Pathol* 1989;68:527-530.
  137. Lynch SE, Williams RC, Polson AM, Howell TH, Reddy MS, Zappa UE. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. *J Clin Periodontol* 1989;16:545-548.
  138. Wozney JM. The potential role of bone morphogenetic proteins in periodontal reconstruction. *J Periodontol* 1995;66:506-510.
  139. Mellonig JT. Enamel matrix derivative for periodontal reconstructive surgery: technique and clinical and histologic case report. *Int J Periodontics Restorative Dent* 1999;19:9-19.
  140. Yukna RA, Callan DP, Krauser JT, et al. Multi-center clinical evaluation of combination anorganic bovine-derived hydroxyapatite matrix (ABM)/cell binding peptide (P-15) as a bone replacement graft material in human periodontal osseous defects. 6-month results. *J Periodontol* 1998;69:655-663.
  141. Sculean A, Donos N, Blaes A, et al. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study. *J Periodontol* 1999;70:255-262.
  142. Pontoriero R, Wennstrom J, Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical trial. *J Clin Periodontol* 1999;26:833-840.
  143. The American Academy of Periodontology. *Periodontal Regeneration* (position paper). Chicago: The American Academy of Periodontology; May 1993.
  144. Garrett S. Periodontal regeneration around natural teeth. *Ann Periodontol* 1996;1:621-666.
  145. The American Academy of Periodontology. *Reconstructive Periodontal Surgery* (position paper) Chicago: The American Academy of Periodontology; May 1992.
  146. Grossi SG, Skrepcinski FB, DeCaro T, Zambon JJ, Cummins D, Genco RJ. Response to periodontal therapy in diabetics and smokers. *J Periodontol* 1996;67:1094-1102.
  147. Zambon JJ, Grossi SG, Machtei EE, Ho AW, Dunford R, Genco RJ. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. *J Periodontol* 1996;67:1050-1054.
  148. Rosen PS, Marks MH, Reynolds MA. Influence of smoking on long-term clinical results of intrabony defects treated with regenerative therapy. *J Periodontol* 1996;67:1159-1163.
  149. Preber H, Bergström J. The effect of non-surgical treatment on periodontal pockets in smokers and non-smokers. *J Clin Periodontol* 1986;13:319-323.
  150. Preber H, Bergström J. Effect of cigarette smoking on periodontal healing following surgical therapy. *J Clin Periodontol* 1990;17:324-328.
  151. The American Academy of Periodontology *Tobacco Use and the Periodontal Patient* (position paper). Chicago: The American Academy of Periodontology; September 1995.
  152. Comar MD, Kollar, Gargiulo AW. Local irritation and occlusal trauma as co-factors in the periodontal disease process. *J Periodontol* 1969;40:193-200.
  153. Polson AM, Meitner SW, Zander HA. Trauma and progression of marginal periodontitis in squirrel monkeys. III. Adaptation of interproximal alveolar bone to repetitive injury. *J Periodont Res* 1976;11:278-289.
  154. Polson AM, Meitner SW, Zander HA. Trauma and progression of marginal periodontitis in squirrel monkeys. IV. Reversibility of bone loss due to trauma alone and trauma superimposed upon periodontitis. *J Periodont Res* 1976;11:290-297.
  155. Perrier M, Polson A. The effect of progressive and increasing tooth hypermobility on reduced but healthy periodontal supporting tissues. *J Periodontol* 1982;53:152-157.
  156. Lindhe J, Ericsson I. The effect of elimination of jiggling forces on periodontally exposed teeth in the dog. *J Periodontol* 1982;53:562-567.
  157. Neiderud A-M, Ericsson I, Lindhe J. Probing pocket depth at mobile and nonmobile teeth. *J Clin Peri-*

- odontol* 1992;19:754-759.
158. Burgett FG, Ramfjord SP, Nissle RR et al. A randomized trial of occlusal adjustment in the treatment of periodontitis patients. *J Clin Periodontol* 1992;19:381-387.
  159. Harrel SK, Nunn ME. The effect of occlusal discrepancies on periodontitis. II. Relationship of occlusal treatment to the progression of periodontal disease. *J Periodontol* 2001;72:495-505.
  160. Gehr M. Non-surgical pocket therapy: Dental occlusion. *Ann Periodontol* 1996;1:567-580.
  161. Rosling B, Nyman S, Lindhe J, Jern B. The healing potential of the periodontal tissues following different techniques of periodontal surgery in plaque-free dentitions. *J Clin Periodontol* 1976;3:233-250.
  162. The American Academy of Periodontology *Supportive Periodontal Therapy (SPT)* (position paper). Chicago: The American Academy of Periodontology December, 1997.

Individual copies of this paper may be obtained by accessing the Academy's Web site at <http://www.perio.org>. Members of the American Academy of Periodontology have permission of the Academy as copyright holder, to reproduce up to 150 copies of this document for not-for-profit, educational purposes only. For information on reproduction of the document for any other use or distribution, please contact Managing Editor Julie Daw at the Academy Central Office; voice: 312/573-3224; fax: 312/573-3225; e-mail: [julie@perio.org](mailto:julie@perio.org).